Abstract
The prodrug design is a versatile, powerful method that can be applied to a wide range of parent drug molecules, administration routes, and formulations. Clinically, the majority of prodrugs are used with the aim of enhancing drug permeation by increasing lipophilicity, or by improving aqueous solubility. Prodrug design may improve the bioavailability of parent molecule, and thus can be integrated into the iterative process of lead optimization, rather than employing it as a post-hoc approach. The purpose of this review is to provide an update of advances and progress in the knowledge of current strategic approaches of prodrug design, along with their real-world utility in drug discovery and development. The review covers the type of prodrugs and functional groups that are amenable to prodrug design. Various prodrug approaches for improving oral drug delivery are discussed, with numerous examples of marketed prodrugs, including improved aqueous solubility, improved lipophilicity, transporter-mediated absorption, and prodrug design to achieve site-specific delivery. Tools employed for prodrug screening, and specific challenges in prodrug research and development are also elaborated. This article is intended to encourage discovery scientists to be creative and consider a rationally designed prodrug approach during the lead optimization phase of drug discovery programs, when the structure activity relationship (SAR) for the drug target is incompatible with pharmacokinetic or biopharmaceutical objectives.
Keywords: Absorption, bioavailability, carrier-mediated transport, drug targeting, permeability, prodrug, solubility, transporter, lipophilicity, transporter-mediated absorption, structure ac-tivity relationship (SAR), pharmacokinetic properties, intestinal epithelium, blood-brain barrier, distribution, metabolism, and excretion (ADME), Bioprecursor, sulindac, Losartan, Oxidative, cyclophosphamide, antiproliferative agent, neoplastic cells, hypoxia, antiparasitic, nitroarenes, metronidazol, antimicrobial prodrugs, antitubercular, nitroimidazooxazine, cytotoxic agents, Bopindolol, Dipivefrine, Glaucoma, Spirapril, Melevodapa, Mestranol, Nitazoxamide, Terfenadine, Viramidine, omeprazole action, Carrier-linked prodrugs, oseltamivir, bambuterol, bacampicillin, oximes, Quinapril, Enalapril, angiotensin-converting enzyme (ACE), Phosphate Ester Prodrugs, Acyloxyalkyl Prodrugs, Carbamate Prodrugs, Docarpamine, Schiff Base Prodrugs, γ-aminobutyric acid (GABA), P-glycoprotein, enterocyte, protease inhibitors, desglymidodrine, Gabapentin, colonic mucosa, Chemical delivey System (CDS), Sulfasalazine, Tumour Targeting, Capecitabine, antibody-directed enzyme prodrug therapy (ADEPT), gene-directed enzyme prodrug therapy (GDEPT), Nitroreductase, nucleoside monophosphonate (NMP), 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA), Simvastatin, Lovastatin, Caco-2, nalbuphine, fosphenytoin, hydroxyethylnicotinamide, adefovir dipivoxil, polymorphism, tenofovir disoproxil, Acyclovir, Hepatic clearance, Gancyclovir
Current Medicinal Chemistry
Title: Prodrug Design to Improve Pharmacokinetic and Drug Delivery Properties: Challenges to the Discovery Scientists
Volume: 17 Issue: 32
Author(s): S. Jana, S. Mandlekar and P. Marathe
Affiliation:
Keywords: Absorption, bioavailability, carrier-mediated transport, drug targeting, permeability, prodrug, solubility, transporter, lipophilicity, transporter-mediated absorption, structure ac-tivity relationship (SAR), pharmacokinetic properties, intestinal epithelium, blood-brain barrier, distribution, metabolism, and excretion (ADME), Bioprecursor, sulindac, Losartan, Oxidative, cyclophosphamide, antiproliferative agent, neoplastic cells, hypoxia, antiparasitic, nitroarenes, metronidazol, antimicrobial prodrugs, antitubercular, nitroimidazooxazine, cytotoxic agents, Bopindolol, Dipivefrine, Glaucoma, Spirapril, Melevodapa, Mestranol, Nitazoxamide, Terfenadine, Viramidine, omeprazole action, Carrier-linked prodrugs, oseltamivir, bambuterol, bacampicillin, oximes, Quinapril, Enalapril, angiotensin-converting enzyme (ACE), Phosphate Ester Prodrugs, Acyloxyalkyl Prodrugs, Carbamate Prodrugs, Docarpamine, Schiff Base Prodrugs, γ-aminobutyric acid (GABA), P-glycoprotein, enterocyte, protease inhibitors, desglymidodrine, Gabapentin, colonic mucosa, Chemical delivey System (CDS), Sulfasalazine, Tumour Targeting, Capecitabine, antibody-directed enzyme prodrug therapy (ADEPT), gene-directed enzyme prodrug therapy (GDEPT), Nitroreductase, nucleoside monophosphonate (NMP), 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA), Simvastatin, Lovastatin, Caco-2, nalbuphine, fosphenytoin, hydroxyethylnicotinamide, adefovir dipivoxil, polymorphism, tenofovir disoproxil, Acyclovir, Hepatic clearance, Gancyclovir
Abstract: The prodrug design is a versatile, powerful method that can be applied to a wide range of parent drug molecules, administration routes, and formulations. Clinically, the majority of prodrugs are used with the aim of enhancing drug permeation by increasing lipophilicity, or by improving aqueous solubility. Prodrug design may improve the bioavailability of parent molecule, and thus can be integrated into the iterative process of lead optimization, rather than employing it as a post-hoc approach. The purpose of this review is to provide an update of advances and progress in the knowledge of current strategic approaches of prodrug design, along with their real-world utility in drug discovery and development. The review covers the type of prodrugs and functional groups that are amenable to prodrug design. Various prodrug approaches for improving oral drug delivery are discussed, with numerous examples of marketed prodrugs, including improved aqueous solubility, improved lipophilicity, transporter-mediated absorption, and prodrug design to achieve site-specific delivery. Tools employed for prodrug screening, and specific challenges in prodrug research and development are also elaborated. This article is intended to encourage discovery scientists to be creative and consider a rationally designed prodrug approach during the lead optimization phase of drug discovery programs, when the structure activity relationship (SAR) for the drug target is incompatible with pharmacokinetic or biopharmaceutical objectives.
Export Options
About this article
Cite this article as:
Jana S., Mandlekar S. and Marathe P., Prodrug Design to Improve Pharmacokinetic and Drug Delivery Properties: Challenges to the Discovery Scientists, Current Medicinal Chemistry 2010; 17 (32) . https://dx.doi.org/10.2174/092986710793205426
DOI https://dx.doi.org/10.2174/092986710793205426 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurotrophic Factor Treatment After Spinal Root Avulsion Injury
Central Nervous System Agents in Medicinal Chemistry Neovascular Age-related Macular Degeneration: Past, Present, and Future
Current Angiogenesis (Discontinued) Does Erythropoietin Always Win?
Current Medicinal Chemistry Peptide Therapeutics in Neurodegenerative Disorders
Current Medicinal Chemistry Mechanisms of HIV Neuropathogenesis: Role of Cellular Communication Systems
Current HIV Research The Glial Sodium-Calcium Exchanger: A New Target for Nitric Oxide- Mediated Cellular Toxicity
Current Protein & Peptide Science Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Carbonic Anhydrase Inhibitors as Anticonvulsant Agents
Current Topics in Medicinal Chemistry Triamcinolone Acetonide Inhibits p38MAPK Activation and Neuronal Apoptosis in Early Diabetic Retinopathy
Current Molecular Medicine A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry Hypoxia PET Tracers in EBRT Dose Planning in Head and Neck Cancer
Current Radiopharmaceuticals Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry The Mechanism of Dead-in-Bed Syndrome and Other Sudden Unexplained Nocturnal Deaths
Current Diabetes Reviews S-Nitrosylation: Targets, Controls and Outcomes
Current Genomics Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Depressed Glucose Consumption at Reperfusion following Brain Ischemia does not Correlate with Mitochondrial Dysfunction and Development of Infarction: An in vivo Positron Emission Tomography Study
Current Neurovascular Research Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Perivascular Adipose Tissue, Inflammation and Vascular Dysfunction in Obesity
Current Vascular Pharmacology MicroRNAs as Cancer Biomarkers
MicroRNA Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry